Delcath Systems, Inc. DCTH
19.94 USD -0.34 (-1.65%)
Nov 10, 2026, 1:57 PM EST
19.51 Day range 21.79
8.12 52-week range 21.79
- YTD
- +97.38%
- 1 year
- +132.34%
- Market cap
- 691.72M
- Revenue (ttm)
- 11.88M
- EPS (ttm)
- 0.16
- Shares out
- 31.97M
- P/E ratio
- 124.59
- Forward P/E
- -35.75
- YTD return
- +97.38%
- 1-year return
- +132.34%
- Volume
- 1.49M
- Avg volume
- 444.01K
- Open
- 20.20
- Previous close
- 20.27
- Day's range
- 19.51 – 21.79
- 52-week range
- 8.12 – 21.79
- Beta
- 0.76
- Analysts
- Strong Buy
- Price target
- 21.33 (+7.0%)
5D +6.04 (+42.45%)
Key statistics
- Enterprise value
- 307.80M
- PEG ratio
- 0.00
- Price / sales
- 30.79
- Price / book
- 16.51
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 1468.90%
- Free cash flow
- -16.64M
- Total cash
- 19.91M
- Total debt
- 5.58M
- Return on equity
- -478.59%
- Short % of float
- 4.46%
- 50-day average
- 10.72
- 200-day average
- 8.12
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 21.33 +7.0% upside
Now 19.94
- Target (low)
- 18.00
- Target (mean)
- 21.33
- Target (high)
- 25.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
- Strong buy2
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.02.
Financials — quick view
DCTH Revenue — quarterly 29.13M
DCTH Net income — quarterly 2.67M
DCTH EPS — quarterly 0.07
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.13 | -0.03 | +0.10 | +76.92% |
| Aug 5, 2024 | Jun 1, 2024 | -0.34 | -0.48 | -0.14 | -41.18% |
| May 14, 2024 | Mar 1, 2024 | -0.43 | -0.43 | 0.00 | 0.00% |
| Mar 26, 2024 | Dec 1, 2023 | -0.67 | -0.48 | +0.19 | +28.36% |
| Nov 13, 2023 | Sep 1, 2023 | -0.51 | -0.61 | -0.10 | -19.61% |
| Aug 9, 2023 | Jun 1, 2023 | -0.67 | -0.58 | +0.09 | +13.43% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 6, 2024 | Stephens & Co. | reit | Overweight | Overweight |
| Aug 6, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 28, 2024 | Craig-Hallum | init | — | Buy |
| May 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| May 14, 2024 | Stephens & Co. | init | — | Overweight |
About Delcath Systems, Inc.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- delcath.com
News
HC Wainwright & Co. Maintains Buy on Delcath Systems, Raises Price Target to $36 
Crude Oil Falls Over 3%; NRG Energy Shares Jump After Strong Q3 Results 
12 Health Care Stocks Moving In Monday's Intraday Session 
CNH Industrial, Planet Labs, Ferguson Enterprises And Other Big Stocks Moving Higher On Monday 
BTIG Maintains Buy on Delcath Systems, Raises Price Target to $25 
Delcath Systems Q3 2026 Earnings Call Transcript 
Delcath Systems Raises FY2026 Sales Guidance from $104.000M-$108.000M to $115.000M-$117.000M vs $106.507M Est 
Delcath Systems Q3 EPS $0.17 Beats $(0.09) Estimate, Sales $35.102M Beat $26.027M Estimate 
Delcath Systems: Intriguingly Poised Ahead Of Q3 Earnings 
Delcath Systems Presents Data Regarding Its Clinical Development Programs At European Society For Medical Oncology Congress 2026; Presents Publication Of Analysis Of Percutaneous Hepatic Perfusion With Melphalan Using CHEMOSAT Hepatic Delivery Systems
Your note
Sign in to keep a note on DCTH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AHARON GILAD S. | Director | Conversion of Exercise of derivative security | Apr 17, 2024 | 0 |
| HOFFMAN DAVID L | General Counsel | Stock Award(Grant) | Mar 18, 2024 | 74,330 |
| MICHEL GERARD J | Chief Executive Officer | Conversion of Exercise of derivative security | Oct 21, 2024 | 319,334 |
| MUIR KEVIN | Officer | Stock Award(Grant) | Mar 18, 2024 | 18,582 |
| PENNELL SANDRA | Officer | Stock Award(Grant) | Mar 18, 2024 | 61,052 |
| PURPURA JOHN | Chief Operating Officer | Purchase | Oct 12, 2023 | 41,526 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Essex Investment Management Co LLC | 0.00% | 336,722 | 3.85M | Sep 29, 2024 |
| Rosalind Advisors, Inc. | 0.00% | 2,650,389 | 30.32M | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.00% | 251,895 | 2.88M | Sep 29, 2024 |
| Cibc World Markets, Inc. | 0.00% | 200,492 | 2.29M | Sep 29, 2024 |
| AIGH Capital Management LLC | 0.00% | 1,782,490 | 20.39M | Sep 29, 2024 |
| Vanguard Group Inc | 0.00% | 1,110,707 | 12.71M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| 1290 Fds-1290 Essex Small Cap Growth Fd | 85.94% | 62,544 | 715.50K | Jul 30, 2024 |
| iShares Micro Cap ETF | 64.26% | 46,767 | 535.01K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 62.57% | 45,531 | 520.87K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 44.27% | 32,218 | 368.57K | Oct 30, 2024 |
| Vanguard Balanced Index Fund | 36.02% | 26,212 | 299.87K | Sep 29, 2024 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 24.33% | 17,705 | 202.54K | Sep 29, 2024 |